Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2000-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/00004714-200002000-00007PMID 10653206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

  2005cited by this paper
• Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.

  2003cited by this paper
• The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.

  2003cited by this paper
• Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients.

  1998cited by this paper
• Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.

  1998cited by this paper
• Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

  1998cited by this paper
• Clozapine and fluvoxamine, a curious complexity.

  1998cited by this paper
• Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.

  1997cited by this paper
• Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.

  1997cited by this paper
• N-oxygenation of clozapine by flavin-containing monooxygenase.

  1997cited by this paper
• Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.

  1997cited by this paper
• Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.

  1997cited by this paper
• Fluvoxamine—Clozapine Dose-Dependent Interaction

  1996cited by this paper
• Fluvoxamine increases the clozapine serum levels significantly.

  1996cited by this paper
• Elevated clozapine levels after fluvoxamine initiation.

  1996cited by this paper
• Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.

  1996cited by this paper
• [Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].

  1996cited by this paper
• Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex.

  1995cited by this paper
• Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.

  1995cited by this paper
• Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service

  1994cited by this paper
• Elevated levels of clozapine in serum after addition of fluvoxamine.

  1994cited by this paper
• Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.

  1994cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

  1992cited by this paper
• Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients

  1992cited by this paper
• A case report of cimetidine-induced clozapine toxicity.

  1991cited by this paper
• Influence of patient-related variables on clozapine plasma levels.

  1990cited by this paper
• EZ-FIT: a practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers.

  1988cited by this paper
• On the evaluation of the constants Vm and KM in enzyme reactions.

  1952cited by this paper

• The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations

  2025cites this paper
• Validation of Population Pharmacokinetic Models for Clozapine Dosage Prediction

  2024cites this paper
• [Experience of clinical use of fluvoxamine for the treatment of comorbid depression in childhood and adolescence].

  2023cites this paper
• Obsessions and Delusions: The Clinical Overlap and Differential Diagnosis of Obsessive-Compulsive and Psychotic Disorders

  2023cites this paper
• Does the Starting of Clozapine Influence Coprescription of Other Medications?

  2021cites this paper
• Possible pharmacogenetic factors in clozapine treatment failure: a case report

  2021cites this paper
• Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.

  2019cites this paper
• Schizophrenia and Other Psychotic Disorders ( J Csernansky , Section Editor ) Treatment of Clozapine Nonresponders

  2019cites this paper
• The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy

  2019cites this paper
• Treatment-Resistant Schizophrenia: Assessment and Management

  2018cites this paper
• A case for adding fluvoxamine to clozapine

  2018cites this paper
• Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2‐ and CYP3A4‐selective Inhibitors

  2018cites this paper
• Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.

  2017cites this paper
• Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement

  2016cites this paper
• An ex Vivo Model for Evaluating Blood-Brain Barrier Permeability, Efflux, and Drug Metabolism.

  2016cites this paper
• Comparison Of Effect Of Addition Of Fluvoxamine Or Risperidone To Clozapine In Chronic Partially Responsive Schizophrenic Patients On Clinical Response, QTc interval And Lipid profile

  2016cites this paper
• Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

  2015cites this paper
• How should we manage anxiety in patients with schizophrenia?

  2015cites this paper
• Comparative Cytochrome P 450 In Vitro Inhibition by Atypical Antipsychotic Drugs

  2015cites this paper
• Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

  2014cites this paper
• Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension

  2014cites this paper
• Selective serotonin reuptake inhibitor drug interactions in patients receiving statins.

  2014cites this paper
• A Current Review of Cytochrome P450 Interactions of Psychotropic Drugs

  2014cites this paper
• Clozapine-associated Development of Second-onset Obsessive Compulsive Symptoms in Schizophrenia: Impact of Clozapine Serum Levels and Fluvoxamine Add-on

  2014cites this paper
• Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals

  2013cites this paper
• An Exploratory Study Examining Lipid-Lowering Medications in Reducing Fasting Serum Lipids in Schizophrenia Patients Treated with Atypical Antipsychotics

  2013cites this paper
• Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs

  2013influential citation
• Clinically Significant Drug Interactions with Atypical Antipsychotics

  2013cites this paper
• Physicians' responses to computerized drug-drug interaction alerts for outpatients

  2013cites this paper
• Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.

  2013cites this paper
• Central Nervous System Drugs

  2012cites this paper
• Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.

  2012cites this paper
• Clinically relevant drug interactions in anxiety disorders

  2012cites this paper
• TOOLS IN PHARMACOVIGILANCE IN PSYCHIATRY: THERAPEUTIC DRUG MONITORING, PHARMACOGENETIC TESTS AND DRUG-DRUG INTERACTIONS DATABASES

  2011cites this paper
• The utility of semi-automating multiplexed assays for ADME/Tox applications.

  2011cites this paper
• Automated Luminescence-Based Cytochrome P450 Profiling Using a Simple, Elegant Robotic Platform

  2011cites this paper
• Augmentative Effects of Fluvoxamine on Duloxetine Plasma Levels in Depressed Patients

  2011cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• Effects of glycyrrhetic acid and glycyrrhetinic acid on the inhibiting cytochrome P450 Activities of brucine and strychnine in vitro test

  2009cites this paper
• Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.

  2009cites this paper
• Asian Journal of Pharmacodynamics and Pharmacokinetics

  2009cites this paper
• Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.

  2009cites this paper
• Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.

  2008cites this paper
• Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.

  2008cites this paper
• A quantitative index of substrate promiscuity.

  2008cites this paper
• Metabolic drug interactions with newer antipsychotics: a comparative review.

  2007cites this paper
• Inefficacité de la clozapine en rapport avec un métabolisme augmenté et intérêt de la fluvoxamine : à propos de quatre cas

  2007cites this paper
• Clozapine case series.

  2007cites this paper
• Drug-Drug Interactions with Antipsychotics

  2007cites this paper
• [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].

  2007cites this paper
• CYP-mediated clozapine interactions: how predictable are they?

  2007cites this paper
• Role of CYP pharmacogenetics and drug‐drug interactions in the efficacy and safety of atypical and other antipsychotic agents

  2006influential citation
• Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.

  2006cites this paper
• Luminogenic cytochrome P450 assays

  2006cites this paper
• Study of inhibition of six new drugs on five human cytochrome P450 isozymes in vitro system

  2006cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance

  2006cites this paper
• Fluvoxamine as an adjunctive agent in schizophrenia.

  2006cites this paper
• Antidepressant–Drug Interactions are Potentially but Rarely Clinically Significant

  2006influential citation
• An overview of psychotropic drug-drug interactions.

  2005cites this paper
• Effect of ginseng extract and ginsenosides on activity of cytochrome P450

  2005cites this paper
• Toxic clozapine serum levels during acute urinary tract infection: a case report

  2005cites this paper
• IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

  2005cites this paper
• DRUG-DRUG INTERACTIONS : CYP 2 D 6 PARADIGM

  2005cites this paper
• Pharmacokinetic Factors in the Adverse Cardiovascular Effects of Antipsychotic Drugs

  2004cites this paper
• EEG spectral power and mean frequencies in early heroin abstinence.

  2004cites this paper
• Dose‐Dependent Alternations in the Pharmacokinetics of Olanzapine During Coadministration of Fluvoxamine in Patients With Schizophrenia

  2004cites this paper
• Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

  2004cites this paper
• Maximum Recommended Doses of Local Anesthetics: A Multifactorial Concept

  2004cites this paper
• The Differential Effects of Steady‐State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers

  2004cites this paper
• Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.

  2004cites this paper
• Reduction of clozapine-induced hypersalivation by pirenzepine is safe.

  2004cites this paper
• Reduction Of Clozapine-Induced Hypersalivation By Pirenzepine Is Safe

  2004cites this paper
• Interactions between the cytochrome P450 system and the second-generation antipsychotics.

  2003cites this paper
• Adjunctive fluvoxamine with clozapine.

  2003cites this paper
• Delirium During Clozapine Treatment: Incidence and Associated Risk Factors

  2003cites this paper
• Olanzepine-induced tardive dyskinesia.

  2003cites this paper
• Racial discrimination and mental illness.

  2003cites this paper
• Effects of drug interactions and liver disease on the pharmacokinetics of ropivacaine

  2003cites this paper
• Pharmacokinetic interactions of clozapine in hospitalized patients

  2003cites this paper
• Racial discrimination and mental illness.

  2003cites this paper
• Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

  2003influential citation
• The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

  2002cites this paper
• Serotonin-selektive Antidepressiva(SSRI, DSA)

  2002cites this paper
• Med-psych drug-drug interactions update.

  2002cites this paper
• Comments on in vitro and in vivo studies of fluvoxamine-clozapine interaction.

  2002cites this paper
• Human CYPs: in vivo and clinical aspects

  2002cites this paper
• Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

  2002cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Dosing strategies of clozapine-fluvoxamine cotreatment.

  2002cites this paper
• Fluvoxamineof its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents

  2001cites this paper
• Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

  2001cites this paper
• Effects of induction and inhibition of Cytochrome P-450 enzymes on the pharmacokinetics and pharmacodynamics of oral antidiabetic drugs

  2001cites this paper
• Fluvoxamine

  2001cites this paper
• CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia

  2001cites this paper
• Fluvoxamine‐theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2

  2001cites this paper
• Auftreten von Nebenwirkungen unter Clozapin-Fluvoxamin-Kombination

  2001cites this paper
• CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

  2001cites this paper
• Pharmacogenetics for the Individualization of Psychiatric Treatment

  2001cites this paper
• Comment: Unanticipated Plasma Concentrations in Two Clozapine-Treated Patients

  2001cites this paper
• Lack of CYP3A4 Inhibition by Grapefruit Juice and Ketoconazole upon Clozapine Administration in Vivo

  2001cites this paper